CARDIOVASCULAR JOURNAL OF AFRICA • Vol 21, No 1, January/February 2010
AFRICA
45
TABLE 1. ADJUSTEDWITHIN-TRIAL COST COMPARISON OF FENOFIBRATEVERSUS PLACEBO:
FIVE-YEAR FOLLOW-UP COHORT OF THE FIELD STUDY
Event comparison/1 000 person years at risk
Cost comparison
Placebo
Fenofibrate Cost per unit (ZAR)
Placebo
Fenofibrate
Difference
Non-fatal MI
8.4
6.4
R 110 475**
R 927 990
R 707 040
R–220 950
Coronary angiography
8.4
6.4
R 17 298***
R 145 304
R 110 708
R–34 596
Stroke
7.1
6.4
R 54 739
#
R 388 647
R 350 330
R–38 317
Coronary revascularisation
15.0
11.9
R 127 937***
R 1 919 048 R 1 522 445
R–396 603
Other revascularisation
4.7
3.9
R 19 734
#
R 92 748
R 76 961
R–15 787
R–706 254 in favour of fenofibrate
Treatment comparison/1 000 person years of treatment
Cost comparison
Placebo
Fenofibrate Cost per annum (ZAR)
Placebo
Fenofibrate
Difference
Lipid-lowering therapy
4.4
2.1
R 1 530*
R 6 734
R 3 214
R–3 520
Fenofibrate therapy
–
25.2
R 3 488
##
–
R 87 901
R 87 901
R 84 381 in favour of standard treatment
Total cost
Placebo
Fenofibrate
Difference (%)
Cost saving of R–621 873 per 1 000 patient years of treatment with fenofibrate
R 3 480 471 R 2 858 598
18%
*Simvastatin 10 mg (30);
#
Solution data; **Medihelp data; ***Healthcorp data;
##
Retail ex VAT
TABLE 2. ADJUSTEDWITHIN-TRIAL COST COMPARISON OF FENOFIBRATEVERSUS PLACEBO:
FIVE-YEAR FOLLOW-UP COHORT OF THE FIELD STUDY BASED ON 95% CI FOR OBSERVED EVENT RATES:
HIGHER 95% CONFIDENCE LIMITS
Event comparison/1 000 person years at risk
Cost comparison
Placebo
Fenofibrate Cost per unit (ZAR)
Placebo
Fenofibrate
Difference
Non-fatal MI
8.4
5.2
R 110 475**
R 927 990
R 574 470
R–353 520
Coronary angiography
8.4
5.2
R 17 298***
R 145 304
R 89 950
R–55 354
Stroke
7.1
4.7
R 54 739
#
R 388 647
R 257 273
R–131 374
Coronary revascularisation
15.0
10.2
R 127 937***
R 1 919 048 R 1 304 953
R–614 095
Other revascularisation
4.7
3.3
R 19 734
#
R 92 748
R 65 121
R–27 627
R–1 181 970 in favour of fenofibrate
Treatment comparison/1 000 person years of treatment
Cost comparison
Placebo
Fenofibrate Cost per annum (ZAR)
Placebo
Fenofibrate
Difference
Lipid-lowering therapy
4.4
2.1
R 1 530*
R 6 734
R 3 214
R–3 520
Fenofibrate therapy
–
25.2
R 3 488
##
–
R 87 901
R 87 901
R 84 381 in favour of standard treatment
Total cost
Placebo
Fenofibrate
Difference (%)
Cost saving of R–1 097 589 per 1 000 patient years of treatment with fenofibrate
R 3 480 471 R 2 382 882
32%
*Simvastatin 10mg (30);
#
Solution data; **Medihelp data; ***Healthcorp data;
##
Retail ex VAT
TABLE 3. ADJUSTEDWITHIN-TRIAL COST COMPARISON OF FENOFIBRATEVERSUS PLACEBO:
FIVE-YEAR FOLLOW-UP COHORT OF THE FIELD STUDY BASED ON 95% CI FOR OBSERVED EVENT RATES:
LOWER 95% CONFIDENCE LIMIT
Event comparison/1 000 person years at risk
Cost comparison
Placebo
Fenofibrate Cost per unit (ZAR)
Placebo
Fenofibrate
Difference
Non-fatal MI
8.4
7.9
R 110 475**
R 927 990
R 872 753
R–55 238
Coronary angiography
8.4
7.9
R 17 298***
R 145 304
R 136 655
R–8 649
Stroke
7.1
7.9
R 54 739
#
R 388 647
R 432 438
R 43 791
Coronary revascularisation
15.0
13.9
R 127 937***
R 1 919 048 R 1 778 318
R–140 730
Other revascularisation
4.7
4.3
R 19 734
#
R 92 748
R 84 855
R–7 893
R–168 719 in favour of fenofibrate
Treatment comparison/1 000 person years of treatment
Cost comparison
Placebo
Fenofibrate Cost per annum (ZAR)
Placebo
Fenofibrate
Difference
Lipid-lowering therapy
4.4
2.1
R 1 530*
R 6 734
R 3 214
R–3 520
Fenofibrate therapy
–
25.2
R 3 488
##
–
R 87 901
R 87 901
R 84 381 in favour of standard treatment
Total cost
Placebo
Fenofibrate
Difference (%)
Cost saving of R–84 338 per 1 000 patient years of treatment with fenofibrate
R 3 480 471 R 3 396 133
2%
*Simvastatin 10mg (30);
#
Solution data; **Medihelp data; ***Healthcorp data;
##
Retail ex VAT
